A descriptive analysis of real-world oncology biosimilar use in Japan

• DOI: 10.1080/14796694.2024.2352405
• Publication Date: 2024-07-01T14:22:09Z
• Authors: Joshua A Roth; Makan Rahshenas; Grégoire Nowacki; Nihar Masurkar; Ahmed Shelbaya; Kentaro Tajima; Stephanie Dorman; Chiho Ono
• Keywords: Biosimilar

To describe patient and treatment characteristics associated with bevacizumab BS-Pfizer, rituximab BS-Pfizer trastuzumab their reference products in Japan.